The stock price of Marker Therapeutics Inc (NASDAQ: MRKR) has dropped by -16.67 compared to previous close of 2.46. Despite this, the company has seen a fall of -25.05% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells
Is It Worth Investing in Marker Therapeutics Inc (NASDAQ: MRKR) Right Now?
Additionally, the 36-month beta value for MRKR is 1.47. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MRKR is 7.67M and currently, short sellers hold a 1.44% ratio of that float. The average trading volume of MRKR on January 22, 2025 was 56.25K shares.
MRKR’s Market Performance
The stock of Marker Therapeutics Inc (MRKR) has seen a -25.05% decrease in the past week, with a -57.82% drop in the past month, and a -36.92% fall in the past quarter. The volatility ratio for the week is 15.79%, and the volatility levels for the past 30 days are at 11.59% for MRKR. The simple moving average for the past 20 days is -32.89% for MRKR’s stock, with a -46.57% simple moving average for the past 200 days.
Analysts’ Opinion of MRKR
Many brokerage firms have already submitted their reports for MRKR stocks, with Piper Sandler repeating the rating for MRKR by listing it as a “Overweight.” The predicted price for MRKR in the upcoming period, according to Piper Sandler is $6 based on the research report published on March 25, 2021 of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see MRKR reach a price target of $6. The rating they have provided for MRKR stocks is “Overweight” according to the report published on March 19th, 2021.
Piper Sandler gave a rating of “Neutral” to MRKR, setting the target price at $2.50 in the report published on May 12th of the previous year.
MRKR Trading at -39.94% from the 50-Day Moving Average
After a stumble in the market that brought MRKR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.78% of loss for the given period.
Volatility was left at 11.59%, however, over the last 30 days, the volatility rate increased by 15.79%, as shares sank -49.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.59% lower at present.
During the last 5 trading sessions, MRKR fell by -25.05%, which changed the moving average for the period of 200-days by -54.95% in comparison to the 20-day moving average, which settled at $3.05. In addition, Marker Therapeutics Inc saw -34.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRKR starting from ELMS STEVE, who purchase 11,085 shares at the price of $3.20 back on Dec 23 ’24. After this action, ELMS STEVE now owns 325,370 shares of Marker Therapeutics Inc, valued at $35,472 using the latest closing price.
New Enterprise Associates 16, the 10% Owner of Marker Therapeutics Inc, purchase 554,250 shares at $3.20 during a trade that took place back on Dec 23 ’24, which means that New Enterprise Associates 16, is holding 1,625,678 shares at $1,773,600 based on the most recent closing price.
Stock Fundamentals for MRKR
Current profitability levels for the company are sitting at:
- -1.89 for the present operating margin
- 0.04 for the gross margin
The net margin for Marker Therapeutics Inc stands at -1.79. The total capital return value is set at -1.37. Equity return is now at value -79.76, with -63.39 for asset returns.
Currently, EBITDA for the company is -11.79 million with net debt to EBITDA at 0.88. When we switch over and look at the enterprise to sales, we see a ratio of 2.4. The receivables turnover for the company is 7.25for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.15.
Conclusion
In conclusion, Marker Therapeutics Inc (MRKR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
